N-PORT filing recap · April 2022

What did ARK Genomic Revolution ETF buy in April 2022?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$2.59B

Positions

Estimated turnover

13.6%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

New positions

ATAIAtaibeckley Inc.$6.90Mreported value+1.61M shares

Increased positions

MASS908 Devices Inc.$64.01Mreported value+498.9K shares+16.1%TWSTTwist Bioscience Corporation$63.54Mreported value+255.0K shares+13.1%ADPTAdaptive Biotechnologies Corporation$61.12Mreported value+1.73M shares+30.6%DNAGinkgo Bioworks Holdings, Inc.$56.94Mreported value+1.25M shares

Reduced positions

EXASExact Sciences Corporation$238.67Mreported value-325.7K shares-7.0%IONSIonis Pharmaceuticals, Inc.$217.91Mreported value-1.09M shares-15.5%TDOCTeladoc Health, Inc.$132.33Mreported value-246.4K shares-5.9%FATEFate Therapeutics, Inc.$122.09Mreported value-93.5K shares

Exited positions

CLLSCellectis SA$18.00Mprior reported value-2.90M shares-100.0%AQBAquabounty Technologies Inc$5.94Mprior reported value-3.36M shares-100.0%EVGNEvogene Ltd.$3.19Mprior reported value-2.30M shares-100.0%PLTRPalantir Technologies Inc.$2.44Mprior reported value-178.2K shares